Emerging agents and regimens for multiple myeloma

The outcomes of multiple myeloma (MM) have been improved significantly with the therapies incorporating proteasome inhibitors (PI), immunomodulatory drugs, monoclonal antibodies (MoAb) and stem cell transplantation. However, relapsed and refractory MM (RRMM) remains a major challenge. Novel agents a...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Yang, Li, Yi, Gu, Huiyao, Dong, Mengmeng, Cai, Zhen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7654052/
https://www.ncbi.nlm.nih.gov/pubmed/33168044
http://dx.doi.org/10.1186/s13045-020-00980-5
_version_ 1783608001166311424
author Yang, Yang
Li, Yi
Gu, Huiyao
Dong, Mengmeng
Cai, Zhen
author_facet Yang, Yang
Li, Yi
Gu, Huiyao
Dong, Mengmeng
Cai, Zhen
author_sort Yang, Yang
collection PubMed
description The outcomes of multiple myeloma (MM) have been improved significantly with the therapies incorporating proteasome inhibitors (PI), immunomodulatory drugs, monoclonal antibodies (MoAb) and stem cell transplantation. However, relapsed and refractory MM (RRMM) remains a major challenge. Novel agents and regimens are under active clinical development. These include new PIs such as ixazomib, marizomib, and oprozomib; new MoAbs such as isatuximab and MOR202; novel epigenetic agent ricolinostat and novel cytokines such as siltuximab. Recently, the first XPO-1 inhibitor, selinexor, was approved for RRMM. BCMA-targeted BiTE, antibody–drug conjugates and CAR-T cells have the potential to revolutionize the therapy for RRMM. In this review, we summarized the latest clinical development of these novel agents and regimens.
format Online
Article
Text
id pubmed-7654052
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-76540522020-11-10 Emerging agents and regimens for multiple myeloma Yang, Yang Li, Yi Gu, Huiyao Dong, Mengmeng Cai, Zhen J Hematol Oncol Review The outcomes of multiple myeloma (MM) have been improved significantly with the therapies incorporating proteasome inhibitors (PI), immunomodulatory drugs, monoclonal antibodies (MoAb) and stem cell transplantation. However, relapsed and refractory MM (RRMM) remains a major challenge. Novel agents and regimens are under active clinical development. These include new PIs such as ixazomib, marizomib, and oprozomib; new MoAbs such as isatuximab and MOR202; novel epigenetic agent ricolinostat and novel cytokines such as siltuximab. Recently, the first XPO-1 inhibitor, selinexor, was approved for RRMM. BCMA-targeted BiTE, antibody–drug conjugates and CAR-T cells have the potential to revolutionize the therapy for RRMM. In this review, we summarized the latest clinical development of these novel agents and regimens. BioMed Central 2020-11-09 /pmc/articles/PMC7654052/ /pubmed/33168044 http://dx.doi.org/10.1186/s13045-020-00980-5 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Yang, Yang
Li, Yi
Gu, Huiyao
Dong, Mengmeng
Cai, Zhen
Emerging agents and regimens for multiple myeloma
title Emerging agents and regimens for multiple myeloma
title_full Emerging agents and regimens for multiple myeloma
title_fullStr Emerging agents and regimens for multiple myeloma
title_full_unstemmed Emerging agents and regimens for multiple myeloma
title_short Emerging agents and regimens for multiple myeloma
title_sort emerging agents and regimens for multiple myeloma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7654052/
https://www.ncbi.nlm.nih.gov/pubmed/33168044
http://dx.doi.org/10.1186/s13045-020-00980-5
work_keys_str_mv AT yangyang emergingagentsandregimensformultiplemyeloma
AT liyi emergingagentsandregimensformultiplemyeloma
AT guhuiyao emergingagentsandregimensformultiplemyeloma
AT dongmengmeng emergingagentsandregimensformultiplemyeloma
AT caizhen emergingagentsandregimensformultiplemyeloma

Ejemplares similares